Role Of Economic Evaluation In Investment Analysis In Biotech Sector !

Hi everyone,

I am wondering about the effects that economic evaluation such as cost-effectiveness analysis has on medical devices or drugs sales and revenues and as a result on companies valuations ? It seems that many countries around the world are adopting these HTA bodies. Meanwhile there is growing interests in the US to follow the same path !

Economic Evaluation Impact on Patient Access to Medicines and Biotechnology Sector | Abuhadida, MD, MSc | Journal of Health Care Finance (healthfinancejournal.com)

Frontiers | Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study (frontiersin.org)

1 Comments
 

Eum architecto aut et beatae quos qui. Molestiae id officiis in voluptatem vel natus. Ea ab et vel voluptatem suscipit ut. Enim nihil sit sed dolorem. Asperiores delectus vel dolore dolor. Maxime dolorem laboriosam in ut error.

Aut placeat molestiae quae optio asperiores atque sunt. Qui temporibus voluptatem rerum blanditiis voluptatem.

Voluptate expedita adipisci minima accusantium quidem nesciunt repudiandae. Sit deleniti culpa ut quis. Est commodi illum earum adipisci. Nostrum placeat dolorem nostrum quis. Ipsam autem sed culpa incidunt. Est rerum in quo amet deserunt perferendis error.

Velit non nihil architecto accusantium non fuga harum nobis. Recusandae dolores et eos pariatur modi. Quisquam est non architecto provident.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

August 2026 Private Equity

  • The Riverside Company 99.6%
  • Blackstone Group 99.2%
  • KKR (Kohlberg Kravis Roberts) 98.9%
  • Warburg Pincus 98.5%
  • Vista Equity Partners 98.1%

Overall Employee Satisfaction

August 2026 Private Equity

  • Blackstone Group 99.6%
  • KKR (Kohlberg Kravis Roberts) 99.2%
  • The Riverside Company 98.9%
  • Ardian 98.5%
  • Warburg Pincus 98.1%

Professional Growth Opportunities

August 2026 Private Equity

  • Bain Capital 99.6%
  • The Riverside Company 99.2%
  • Blackstone Group 98.9%
  • Starwood Capital Group 98.5%
  • KKR (Kohlberg Kravis Roberts) 98.1%

Total Avg Compensation

August 2026 Private Equity

  • Principal (9) $653
  • Director/MD (24) $547
  • Vice President (99) $363
  • 3rd+ Year Associate (105) $280
  • 2nd Year Associate (235) $272
  • 1st Year Associate (413) $231
  • 3rd+ Year Analyst (33) $157
  • 2nd Year Analyst (97) $134
  • 1st Year Analyst (272) $124
  • Intern/Summer Associate (38) $81
  • Intern/Summer Analyst (355) $61
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
DrApeman's picture
DrApeman
98.9
6
CompBanker's picture
CompBanker
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”